

# Speakers



Dr Markus Fido Mfi Bio-Consulting, Austria



Dr Ulrike Herbrand Charles River Laboratories, Germany



Dr Wolf Hagen Holtkamp Paul-Ehrlich Institut, German Federal Agency for Vaccines and **Biomedicines** 



Dr Henno van den Hooven MSD, The Netherlands



Dr Michael Leiss Roche Diagnostics, Germany



Dr Dietmar Reusch Roche Diagnostics, Germany



Markus Roucka VelaLabs, Austria



GMP Certification Programme

Certified Biotech Manager

Technologies



# Live Online Training on 22/23 May 2024



# Highlights

- **Regulatory Aspects** •
- Available Methods e.g. HPLC, MS, Biophysical Methods, Immunochemical Methods, (non-cellular) Bioassays
- Qualification, Validation and Optimisation of Methods
- Host Cell Proteins
- Physicochemical Methods

**Bringing Compliance and** Science together

# Objective

Biopharmaceutical processes and the specifics in the control of these processes are highly complex. Compared to the "classic" chemical pharmaceutical products and processes, they are frequently on a much higher level – as, for instance, in the case of proteins. In addition, the drug product alone possibly poses real challenges due to the restraints created by the nature of the protein.

Over the last years a huge variety of analytical methods – ranging from physicochemical tests to biological assays – have been established.

As the range of biopharmaceuticals is evolving, new tests have to be developed, validated, transferred, applied at the same time. And, last but not least, they have to be accepted by regulatory authorities.

In this Live Online Training, pros and cons of established and newly emerging assays will be discussed. Industry experts will share their in-depth knowledge and experiences. During workshops in small groups, you will deepen your knowledge about special methods and their validation issues.

The course has been designed to answer your individual questions concerning assays for the quality control of proteins. In addition you will benefit from information on bioassays and current hot topics like host cell proteins.

# Background

The number of biopharmaceutical products is increasing, in clinical phases as well as in the market. Due to their high complexity they show an excellent targeting ability. To ensure the quality and targeting ability, a profound analysis of the drug substance's quality is of utmost importance. This particularly applies to protein-based products and in the production of recombinant proteins. However, it cannot be measured by analytical tests alone. Therefore, the development process of all biopharmaceutical products requires non-analytical tests to fully evaluate their functionality and safety. Biopharmaceutical development is thus a multi-disciplinary effort involving many professionals with diverse backgrounds.

# **Target Audience**

This Live Online Training is of interest to those who are involved in

- Quality Control
- Quality Assurance
- Regulatory Affairs
- Research and Development

of proteins, processes and analytical assays in the biopharmaceutical industry.

# Programme

# Why do we Test? What must be Analysed?

- ICH guideline Q6B
- Composition of product (desired product, excipients, impurities, contaminants)
- Application of tests

## Regulatory Aspects on Analytical Methods

- What do we expect from bioanalytical methods?
- Biopharmaceuticals challenges for analytical methods
   Development of novel analytical methods (needs and
- challenges)
  Validation of analytical methods (LOQ)
- valiaation of analy lear method.

## Liquid Chromatography

- Reversed-phase high-performance liquid chromatography
- Size-exclusion chromatography
- Ion-exchange chromatography
- Applications for biopharmaceuticals

### Controlling Host-Cell Impurities in Biopharmaceuticals

- Why HCP analytics?
- Means to analyze HCP and limitations of applied methods
- Control strategy and regulatory expectations

### ELISA, ECL Technologies

- ECL introduction using MesoScaleDiscovery device
- ELISA based setups for PK & immunogenicity
- ECL optimizing immunogenicity assays
- Validation of PK and ADA screening assay

### Mass Spectrometry

- Intact Mass Analysis investigation of antibody heterogeneity
- LC/MS investigation of primary structure and modifications
- Fundamentals of MALDI-MS MALDI-MS as a complementary technique to ESI-MS

#### Characterization of Biotherapeutic Proteins by Size-Exclusion Chromatography Coupled to Native Mass Spectrometry

- Status quo: Methods for therapeutic protein characterization
- Current questions and challenges
- Innovative approaches and methods
- Application and examples

### Bioassays

- Types of assays for different molecules
- Mechanism of Action (MoA) reflecting assays
- Surrogate approaches for tedious primary assays
- Biosimilarity assessment

### Non-Cellular Assays (SPR, Lectin Binding)

- Orthogonal methods to Bioassays
- Prediction of potency with non-cellular assays (surrogate assays)
- Characterization of antibodies and its biosimilars
- Explanation of Surface Plasmon Resonance (SPR) technology and lectin array

### Glycoanalysis

- Glycosylation of protein
- Why glycoanalysis?
- Principles of glycoanalysis
- Separation based methods
- MS based methods
- Comparison of methods for glycoanalysis

# Interactive Session with Case Studies and Practical Examples:

- Immunochemical Methods Dr Markus Fido
- Spectroscopic Analysis and Chromatography Dr Dietmar Reusch & Dr Michael Leiss & Henno van den Hooven
- Cellular Assays Markus Roucka & Dr Ulrike Herbrand

### Additional Methods for Protein Characterization

 Relevant physico-chemical methods – like CD, fluorescence, IR spectroscopy, AUC, SEC-MALLS, DLS, DSC, microflow imaging, etc. and biophysical methods

# Moderator

Axel H. Schroeder, Concept Heidelberg

# Speakers

### Dr Markus Fido, Mfi Bio-Consulting, Austria

Markus Fido holds a doctorate in biochemistry & cell biology. He has worked in quality and product development at Octapharma, Baxter and Igeneon. He then founded Vela Laboratories which he led as CEO for many years. In 2019/2020 he was responsible for the international Pharma Business Development of the Tentamus Group. In May 2020 he founded his new company Mfi Bio Consulting GmbH.

### Dr Ulrike Herbrand, Charles River Laboratories, Germany

Ulrike Herbrand joined Charles River Laboratories in 2007. She is Scientific Director Global in vitro Bioassays and Supervisor for Bioassay Research & Development at Charles River Laboratories' site in Erkrath, Germany. She is an expert in mechanism of action-reflecting bioassays for protein therapeutics, specifically monoclonal antibodies.

#### Dr Wolf Hagen Holtkamp, PEI, German Federal Institute for Vaccines and Biomedicines

Wolf Hagen Holtkamp studied Biochemistry at the Private Universität Witten-Herdecke. He worked as scientist at the University Witten Herdecke and the Max-Planck-Institute for biophysical Chemisty. 2017 he joined the Paul-Ehrlich-Institute as Laboratory Head product testing of immunological medicinal products and batch release control.

### Dr Henno van den Hooven, MSD, The Netherlands

Henno van den Hooven obtained his PhD degree in 1995 in the field of biophysical chemistry at the University of Nijmegen. Until 2017 he was at MSD in Oss, the Netherlands. The responsibilities are mainly for late stage development and cover the field of analytical development of protein drugs. Since 2020 he is working again for MSD as Product Lead Biotech Technical Operations.

### Dr Michael Leiss, Roche Diagnostics, Germany

Michael Leiss studied biochemistry at the University Regensburg and gained his doctorate at the Max Planck Institute of Biochemistry in Munich. He joined Roche in 2009, where he currently holds a position as lab manager, being responsible for biologics batch release testing and analytical method development.

### Dr Dietmar Reusch, Roche Diagnostics, Germany

Dietmar gained his PhD at the Free University of Amsterdam with "Glycosylation analysis of therapeutic antibodies". Since 1988 he is working at Roche Diagnostics. At present Dietmar is heading the Characterisation Analytics department at the Roche facility in Penzberg, Germany.

### Markus Roucka, VelaLabs, Austria

Markus started his career in the biotechnical laboratories of Biomin GmbH. Later he studied medical and pharmaceutical biotechnology at the University of Applied Science IMC Krems. He joined VelaLabs in 2008. Since than he had many stages starting from Head Laboratory to COO. His current position is Managing Director where he is responsible for Customer relations and Business development.

e: Protein Analytics, Live Online Training on 22/23 May 2024	Title, first name, surname	Department Company	Important: Please indicate your company's VAT ID Number Purchase Order Number, if applicable	City ZIP Code Country	Phone / Fax	E-Mail (Please fill in)	CONCEPT HEIDELBERG reserves the right to change the materials, instructors, cellation or non-appearance. If you cannot take part, you have to inform us in Privacy Policy: By registering for this event, I accept the processing of my Perso- or speakers without notice or to cancel an event. If the event must be cancelled, writing. The cancellation fee will then be calculated according to the point of ine at which we receive your message. registrants will be notified as soon as possible and will receive a full refund of time at which we receive your message. registrants will be notified as soon as possible and will receive a full refund of time at which we receive your message. registrants will be notified being will use my data is stored and pro- fees paid. CONCEPT HEIDELBERGWII not be responsible for discount airfare pe- not are not provided as not monormative and providen on the point of the point of the privacy policy. By registrants will be notified as soon as possible and will receive a full refund of in case you do not appear at the event without having informed us, you will have to apple without deductions within 10 days after receipt of ference (receipt of payment; you are entitled to participate in the con- also the privacy policy at http://www.gmp-conpliance.org/leca.privacy.html.l. invoice
tions on the right, please fill out here:				CONCEPT HEIDELBERG P.O. Box 101764 Fax +49 (0) 62 21/84 44 34	D-69007 Heidelberg GERMANY		General terms and conditions f you cannot attend the conference you have two options. 1. We are happy to welcome a substitute colleague at any time. 2. If you have to cancel entirely we must charge the following processing fees: Cancellation until 4 weeks prior to the conference 10 %, Cancellation until 2 weeks prior to the conference 25 %, Cancellation until 2 weeks prior to the conference 50 %,

Reservation Form (Please complete in full)

If the bill-to-address deviates from the specifica-



Date of the Live Online Training Wednesday, 22 May 2024, 09.00 - 18.00 h CEST Thursday, 23 May 2024, 08.30 - 17.00 h CEST

# **Technical Requirements**

We use WebEx for our live online training courses and webinars. https://www.gmp-compliance.org/training/online-training-At technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

# Fees (per delegate, plus VAT)

ECA Members € 1,690 APIC Members € 1,790 Non-ECA Members € 1.890 EU GMP Inspectorates € 945 The conference fee is payable in advance after receipt of invoice.

### Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

### Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

### Conference language

Important: This is a binding registration

The official conference language will be English.

### Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event. CONCEPT HEIDELBERG P.O.Box 10 17 64 69007 Heidelberg, Germany Phone +49(0)62 21 / 84 44-0 Fax +49(0)62 21 / 84 44 34 info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content please contact: Mr Axel H. Schroeder (Operations Director) at +49(0)62 21 / 84 44 10, or at schroeder@concept-heidelberg.de

For questions regarding organisation please contact: Mr Maximillan Bauer (Organisation Manager) at +49(0)62 21 / 84 44 25, or at bauer@concept-heidelberg.de



### Stay informed with the GMP Newsletters from ECA

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, simply scan the QR code or visit www.gmp-compliance.org/ gmp-newsletter

